Literature DB >> 25897900

Amiodarone and Trypanosoma cruzi parasitemia in patients with Chagas disease.

Andre A L Carmo1, Manoel O C Rocha1, Jose L P Silva2, Barbara M Ianni3, Fabio Fernandes3, Ester C Sabino4, Antonio L P Ribeiro5.   

Abstract

Entities:  

Keywords:  Amiodarone; Chagas disease; Parasitemia

Mesh：

Substances：

Year:  2015        PMID： 25897900      PMCID： PMC4446230          DOI： 10.1016/j.ijcard.2015.04.061

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  10 in total

1.  A matching method for improving covariate balance in cost-effectiveness analyses.

Authors:  Jasjeet Singh Sekhon; Richard D Grieve
Journal:  Health Econ       Date:  2011-06-02       Impact factor: 3.046

Review 2.  The emerging role of amiodarone and dronedarone in Chagas disease.

Authors:  Gustavo Benaim; Alberto E Paniz Mondolfi
Journal:  Nat Rev Cardiol       Date:  2012-08-07       Impact factor: 32.419

3.  The National Heart, Lung, and Blood Institute retrovirus epidemiology donor studies (Retrovirus Epidemiology Donor Study and Retrovirus Epidemiology Donor Study-II): twenty years of research to advance blood product safety and availability.

Authors:  Steven Kleinman; Melissa R King; Michael P Busch; Edward L Murphy; Simone A Glynn
Journal:  Transfus Med Rev       Date:  2012-05-24

4.  Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole.

Authors:  Gustavo Benaim; John M Sanders; Yael Garcia-Marchán; Claudia Colina; Renee Lira; Aura R Caldera; Gilberto Payares; Cristina Sanoja; Juan Miguel Burgos; Annette Leon-Rossell; Juan Luis Concepcion; Alejandro G Schijman; Mariano Levin; Eric Oldfield; Julio A Urbina
Journal:  J Med Chem       Date:  2006-02-09       Impact factor: 7.446

5.  Detection of Trypanosoma cruzi DNA in blood by PCR is associated with Chagas cardiomyopathy and disease severity.

Authors:  E C Sabino; A L Ribeiro; T H Lee; C L Oliveira; A B Carneiro-Proietti; A P Antunes; M M Menezes; B M Ianni; V M Salemi; L Nastari; F Fernandes; V Sachdev; D M Carrick; X Deng; D Wright; T T Gonçalez; E L Murphy; B Custer; M P Busch
Journal:  Eur J Heart Fail       Date:  2015-02-10       Impact factor: 15.534

Review 6.  Diagnosis and management of Chagas disease and cardiomyopathy.

Authors:  Antonio L Ribeiro; Maria P Nunes; Mauro M Teixeira; Manoel O C Rocha
Journal:  Nat Rev Cardiol       Date:  2012-07-31       Impact factor: 32.419

7.  Amiodarone and itraconazole: a rational therapeutic approach for the treatment of chronic Chagas' disease.

Authors:  A E Paniz-Mondolfi; A M Pérez-Alvarez; G Lanza; E Márquez; J L Concepción
Journal:  Chemotherapy       Date:  2009-05-19       Impact factor: 2.544

8.  Antibody levels correlate with detection of Trypanosoma cruzi DNA by sensitive polymerase chain reaction assays in seropositive blood donors and possible resolution of infection over time.

Authors:  Ester C Sabino; Tzong-Hae Lee; Lani Montalvo; Megan L Nguyen; David A Leiby; Danielle M Carrick; Marcia M Otani; Elizabeth Vinelli; David Wright; Susan L Stramer; Michael Busch
Journal:  Transfusion       Date:  2012-09-25       Impact factor: 3.157

9.  Ten-year incidence of Chagas cardiomyopathy among asymptomatic Trypanosoma cruzi-seropositive former blood donors.

Authors:  Ester C Sabino; Antonio L Ribeiro; Vera M C Salemi; Claudia Di Lorenzo Oliveira; Andre P Antunes; Marcia M Menezes; Barbara M Ianni; Luciano Nastari; Fabio Fernandes; Giuseppina M Patavino; Vandana Sachdev; Ligia Capuani; Cesar de Almeida-Neto; Danielle M Carrick; David Wright; Katherine Kavounis; Thelma T Goncalez; Anna Barbara Carneiro-Proietti; Brian Custer; Michael P Busch; Edward L Murphy
Journal:  Circulation       Date:  2013-02-07       Impact factor: 29.690

10.  Electrocardiographic abnormalities in Trypanosoma cruzi seropositive and seronegative former blood donors.

Authors:  Antonio L Ribeiro; Ester C Sabino; Milena S Marcolino; Vera M C Salemi; Barbara M Ianni; Fábio Fernandes; Luciano Nastari; André Antunes; Márcia Menezes; Cláudia Di Lorenzo Oliveira; Vandana Sachdev; Danielle M Carrick; Michael P Busch; Eduard L Murphy
Journal:  PLoS Negl Trop Dis       Date:  2013-02-28
  10 in total
  4 in total

1.  Differential cytokine profiling in Chagasic patients according to their arrhythmogenic-status.

Authors:  Héctor Rodríguez-Angulo; Juan Marques; Ivan Mendoza; Marco Villegas; Alfredo Mijares; Núria Gironès; Manuel Fresno
Journal:  BMC Infect Dis       Date:  2017-03-21       Impact factor: 3.090

Review 2.  Developments in the management of Chagas cardiomyopathy.

Authors:  Herbert B Tanowitz; Fabiana S Machado; David C Spray; Joel M Friedman; Oren S Weiss; Jose N Lora; Jyothi Nagajyothi; Diego N Moraes; Nisha Jain Garg; Maria Carmo P Nunes; Antonio Luiz P Ribeiro
Journal:  Expert Rev Cardiovasc Ther       Date:  2015-10-23

3.  A Combination of Itraconazole and Amiodarone Is Highly Effective against Trypanosoma cruzi Infection of Human Stem Cell-Derived Cardiomyocytes.

Authors:  Gabriele Sass; Roy T Madigan; Lydia-Marie Joubert; Adriana Bozzi; Nazish Sayed; Joseph C Wu; David A Stevens
Journal:  Am J Trop Med Hyg       Date:  2019-08       Impact factor: 2.345

Review 4.  Trypanosomatid-Caused Conditions: State of the Art of Therapeutics and Potential Applications of Lipid-Based Nanocarriers.

Authors:  Giuliana Muraca; Ignacio Rivero Berti; María L Sbaraglini; Wagner J Fávaro; Nelson Durán; Guillermo R Castro; Alan Talevi
Journal:  Front Chem       Date:  2020-11-26       Impact factor: 5.221
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.